Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Persicabtagene Lemgedleucel · SC-291

Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by Sana Biotechnology

Phase 1 Most advanced trial
SANA Developer
1 Registered trials

What is Persicabtagene Lemgedleucel?

Persicabtagene lemgedleucel is an allogeneic CAR-T cell therapy made from human T-lymphocytes transduced with a chimeric antigen receptor specific for CD19, with MHC class I and II expression disrupted and CD47 expressed to reduce immune rejection of the donor cells. It is studied in non-Hodgkin lymphoma and chronic lymphocytic leukemia, where it binds CD19-expressing tumor cells and mediates their killing.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SC-291, Cyclophosphamide, Fludarabine
Drug type
Cell therapy (CAR-T)
Targets
CD19 (antigen)
Mechanism
Kills target cells, directed at CD19
Therapy area
Oncology
Developer
Sana Biotechnology (SANA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
9C6AT9DSU2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05878184 Phase 1 Non Hodgkin Lymphoma Active not recruiting SANA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Lymphocytic LeukemiaNon Hodgkin Lymphoma

Other drugs acting on CD19

More from Sana Biotechnology

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SANA page.

Follow SANA, the company behind Persicabtagene Lemgedleucel

See SANA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SANA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.